Oncology News | pharmaphorum

News

J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod

The FDA has approved Johnson & Johnson's Rybrevant Faspro for head and neck cancer, extending the franchise beyond lung cancer for the first time.

News

Bayer's Hyrnuo moves first-line for lung cancer in China

Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.

News

UK biotechs T-Therapeutics and Alethio score big financings

Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.

News

NICE backs Keytruda/Padcev combo for bladder cancer

Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.

News

Boehringer forges $7bn alliance with China's SBP Group

Boehringer Ingelheim is paying $358m upfront for options on up to six antibody-drug conjugates and T-cell engagers from China's Sino Biopharma.

News

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.

J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod

Bayer's Hyrnuo moves first-line for lung cancer in China

UK biotechs T-Therapeutics and Alethio score big financings

NICE backs Keytruda/Padcev combo for bladder cancer

Boehringer forges $7bn alliance with China's SBP Group

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks